225,714,081VANDA PHARMACEUTICALS INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)Nine Months EndedSeptember 30,September 30,20102009Cash flows from operating activities:Net income (loss)
(26,621,456)Adjustments to reconcile net income (loss) to net cash usedin operating activities:Depreciation and amortization257,903346,785Employee and non-employee stock-based compensation3,646,5298,708,726Gain on disposal of assets(23,185)-Amortization of premium/discounts on investments(11,731)122,963Amortization of intangible assets1,118,089606,143Deferred tax benefit(1,554,099)-Changes in assets and liabilities:Prepaid expenses and other current assets190,899(1,345,383)Accounts receivable2,669,870-Inventory2,398,517(1,758,427)Accounts payable(2,128,399)833,854Accrued expenses(545,255)(852,389)Accrued income taxes3,234,732-Other liabilities(12,482)3,061Deferred revenue (20,036,697)-Net cash used in operating activities(5,802,121)(19,956,123)Cash flows from investing activities:Acquisition of intangible asset-(7,000,000)Proceeds from sales of property and equipment66,221-Purchases of investments(124,028,410)(11,365,815)Proceeds from sales of investments-126,547Proceeds from maturities of investments24,500,00015,250,000Net cash used in investing activities(99,462,189)(2,989,268)Cash flows from financing activities:Excess tax benefits from exercise of stock options1,661,988-Proceeds from exercise of stock options774,8161,283,734Net cash provided by financ
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2010 PR Newswire.
All rights reserved